Cuál es el precio por Impact Therap-b (7630)

Precio por Impact Therap-b (7630) es de$1.85

Cuál es la capitalización de mercado por Impact Therap-b (7630)

Capitalización de mercado por Impact Therap-b (7630) es $510.85M

Impact Therap-b (7630) Ratio P/E

IMPACT Therapeutics, a biotechnology firm, specializes in the discovery and advancement of precision anti-cancer treatments rooted in synthetic lethality, operating across China and international markets. The company's primary offering, Senaparib (IMP4297), is a PARP1/2 inhibitor currently deployed as a first-line maintenance therapy for ovarian cancer. Beyond this, Impact Therapeutics maintains a robust pipeline of investigational drugs. This includes IMP1734, a next-generation PARP1 selective inhibitor undergoing Phase I/II trials as a standalone treatment for advanced solid tumors. Another promising candidate is IMP9064, an ATR kinase selective inhibitor, also in Phase I/II clinical studies for advanced solid tumors as a monotherapy. IMP1707, a PARP1 selective inhibitor capable of penetrating the central nervous system, is in Phase I development for homologous recombination repair-deficient tumors. Additionally, IMP7068, an advanced WEE1 inhibitor, is progressing through Phase I/II clinical trials for various advanced solid tumors. Furthermore, a range of other compounds, namely IMP22, IMP25, IMP08, IMP13, IMP10, IMP27, and IMP32, are in the preclinical development phase. The company, established in 2009, is headquartered in Shanghai, China.

Año	Ratio P/E	Cambiar
Not enough data for the provided dates.

Año

Ratio P/E

Cambiar

Not enough data for the provided dates.

Empresa	P/E Ratio	Diferencia del P/E Ratio	País
Eli Lilly and Company LLY.US	39.54	-	US
Johnson & Johnson JNJ.US	30.10	-	US
AbbVie Inc. ABBV.US	70.28	-	US
Roche Holding AG RO.SW	22.25	-	CH
Merck & Co., Inc. MRK.US	107.81	-	US

Empresa

P/E Ratio

Diferencia del P/E Ratio

País